In its opinion of 24 July 2014 on the essential composition of infant and follow-on formulae [EFSA NDA Panel (2014), ‘Scientific Opinion on the essential composition of infant and follow-on formulae’, https://doi.org/10.2903/j.efsa.2014.3760.], the European Food Safety Authority (‘the Authority’) noted that the safety and suitability of each specific formula containing protein hydrolysates has to be established by clinical evaluation in the target population. So far, the Authority has positively evaluated five protein hydrolysates used in infant and follow-on formulae. The composition of those five protein hydrolysates is included in the requirements set out in Delegated Regulation (EU) 2016/127. However, those requirements may be updated in order to allow the placing on the market of a formula manufactured from protein hydrolysates with a different composition from those already positively assessed, following their evaluation by the Authority of their safety and suitability.
Recital 2, Regulation (EU) 2026/743
In forcesince 30 Mar 2026